Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BSTL (Bu Shen Tong Luo) is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Zhejiang Provincial Tongde Hospital for the treatment of non-specific low back pain (NSLBP). The compound is a complex mixture consisting of 12 specific herbal ingredients: BaiShao (9 g), ChuanNiuXi (15 g), DanShen (15 g), DiLong (9 g), DuHuo (9 g), DuZhong (15 g), GouJi (15 g), QinJiao (9 g), SangJiSheng (15 g), XiXianCao (9 g), XuChangQin (9 g), and YanHuSuo (9 g). It is designed to address TCM syndromes associated with back pain, such as kidney deficiency and collateral obstruction. The formulation has been evaluated in a Phase 4 randomized controlled trial (NCT06336993) comparing its clinical efficacy and safety to the non-steroidal anti-inflammatory drug (NSAID) celecoxib in patients with NSLBP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BSTL.